Drug intelligence / Profile preview

APHD-008

Development stage: Unknown
Lead developer: Aphaia Pharma
Modality: Small Molecules
Administration: Oral

Overview

APHD-008 is an oral, site-specific glucose formulation developed by Aphaia Pharma for the treatment of obesity. It is designed to release 8 grams of glucose at discrete locations in the small intestine to restore endogenous nutrient-sensing signaling pathways. This mechanism triggers the release of enteric hormones, such as GLP-1 and PYY, which regulate appetite, satiety, and glucose metabolism. The drug is currently being evaluated in Phase 2 clinical trials, including studies exploring circadian effects on weight loss.

Other names: 8g oral glucose formulation

Targets

GLP1R (GLP-1R)PYY receptor (Peptide YY receptor family)

Beyond the preview

Go deeper on APHD-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APHD-008.

Explore the full profile